VINC (Vincerx Pharma) EBITDA Margin %: 0.00% (As of Mar. 2025)


What is Vincerx Pharma EBITDA Margin %?

Vincerx Pharma VINC EBITDA Margin % is 0.00% as of Mar. 2025.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vincerx Pharma's EBITDA for the three months ended in Mar. 2025 was $-3.33 Mil. Vincerx Pharma's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Vincerx Pharma's EBITDA margin for the quarter that ended in Mar. 2025 was 0.00%.

Vincerx Pharma  (OTCPK:VINC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Vincerx Pharma EBITDA Margin % Related Terms

Vincerx Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Vincerx Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vincerx Pharma EBITDA Margin % Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vincerx Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VINC vs SYGGF, CNBX, LADX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Vincerx Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vincerx Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's EBITDA Margin % falls into.


Vincerx Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Vincerx Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-30.373/0
= %

Vincerx Pharma's EBITDA Margin % for the quarter that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-3.334/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Vincerx Pharma (VINC) has a EBITDA Margin % of 0.00% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vincerx Pharma and its competitors.
Is Vincerx Pharma's EBITDA Margin % too high?
Vincerx Pharma's current EBITDA Margin % is 0.00%.
How does Vincerx Pharma's EBITDA Margin % compare to SYGGF and CNBX?
Vincerx Pharma's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vincerx Pharma and its competitors. Vincerx Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vincerx Pharma stock overvalued right now?
Vincerx Pharma (VINC) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vincerx Pharma (VINC), the current EBITDA Margin % is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vincerx Pharma Business Description

Address 1825 S. Grant Street, San Mateo, CA, USA, 94402
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.